Pathologic examinations play an important role in medical services. Until recently, overall pathologic examination status in Korea has not been investigated. Understanding the current pathologic examination status is important to establishing future plans for resource arrangement. Byeon and Kim \[[@b1-jptm-2016-12-30]\] reported the estimated pathologic examination status in Korea using the Health Insurance Review and Assessment Service (HIRA)--National Patient Sample (NPS). Because the HIRA-NPS data was statistically extracted (selection probability, 0.03), some amount of statistical error is inevitable \[[@b2-jptm-2016-12-30]\]. The current study is a follow-up study using the raw dataset from HIRA. The HIRA dataset did not contain any rejected inspections of insurance reimbursement (IR) requests or new diagnostic techniques that were not approved by various government organizations. However, this dataset is one of the largest medical datasets and it best reflects the current pathologic examination status in Korea. The aims of this study are to estimate the current pathologic examination status according to multiple parameters in Korea, to provide information for future resource arrangement in the pathology era, and to compare differences between NPS and the raw data.

MATERIALS AND METHODS
=====================

I requested HIRA to provide the IRs for various pathologic examinations ([Table 1](#t1-jptm-2016-12-30){ref-type="table"}) from 2011 to 2015 (data extraction was performed in May 2016). The HIRA provided the data after anonymizing the patient identification numbers and hospital identification numbers. Primary data processing was performed using the R Statistical Software (Foundation for Statistical Computing, Vienna, Austria) ver. 3.2.3 in a remote access system for HIRA. Secondary data processing was performed using the R Statistical Software ver. 3.3.1 using the t2.micro instance in the Amazon Elastic Compute Cloud (Amazon, Seattle, WA, USA). To evaluate the tendency of each pathologic examination number from 2011 to 2015, linear regression was applied. A p-value less than .05 was regarded as statistically significant.

I estimated the mean period between IR requests and completion of the IR inspections as follows. Since HIRA did not provide the exact date of completion for the IR inspections and provided their data on a monthly basisinstead, a table containing monthly pathologic examination status from January 2011 to December 2014 was formulated, as seen in [Table 1](#t1-jptm-2016-12-30){ref-type="table"} (pathologic examinations in 2015 were excluded due to incomplete IR request inspections). Using this table as the reference table, I obtained sequentially cumulative data by adding up the monthly number, thereby marking the period pertaining to the 33, 66, and 99 percentile inspections of IR requests. Next, I made up the same table again as sequentially. I obtained the time more than 33, 66 and 99 percentile inspections of IR requests were done.

RESULTS
=======

The abbreviations used in this study are as follows. AC, aspiration cytopathology; BFC, body fluid cytopathology; BONE, histopathologic examination for bone; CB, cell block; CERVIX, cervicovaginal cytopathology; EM, tissue electron microscopy; ENZYME, enzyme histochemistry; FS, emergency histopathologic examination during surgery; HER2 (FISH), *HER2* gene fluorescence *in situ* hybridization; HER2 (SISH), *HER2* gene silver *in situ* hybridization; HR, examination of hormone receptor in tissue; IF, tissue immunofluorescent microscopic examination; IHC, immunohisto(cyto)chemistry; L-, liquid based; LND, with lymph node dissection; LNDX, without lymph node dissection; MaligGro, resected specimen for malignant tumor requiring gross sectioning; MAPPING, histologic mapping of tumor; MSI, microsatellite instability; Non-maligGro, resected specimen requiring gross sectioning; NPB, number of paraffin blocks; OUTSIDE, outside slide interpretation; SPECIAL, special stain examinations.

A summary and the details for annual pathologic examination status are given in [Table 2](#t2-jptm-2016-12-30){ref-type="table"} and [Supplementary Table S1](#SD1-jptm-2016-12-30){ref-type="supplementary-material"}, respectively. Among the main categories, it was found that the total numbers of MAPPING, IF, EM, IHC, CERVIX, and BFC increased during 2011--2015, while the total numbers of ENZYME and CB were decreased. In more detail, the following pathologic examinations increased in 2011--2015: non-maligGro with NPB ≤6, MAPPING LND, MAPPING LNDX, Masson's trichrome stain, IF (IgG, IgA, IgM, C3, C4, fibrinogen, others), EM, IHC (interpretation by qualified doctor, HR, EGFR pharmDx kit), L-CERVIX, L-BFC, L-AC, CB after L-AC, and some of OUTSIDE (C5500009, C5912009, C5916009, C5917009). The following pathologic examinations decreased in 2011-2015: biopsy (more than 13 pieces), IF (IgE and hepatitis B surface antigen), ENZYME (acetylcholinesterase), CERVIX by smear, BFC (general), AC (conventional), and CB (AC). Note that no chloroacetate esterase examinations were performed during the last 5 years.

Most medical and dental departments requested various pathologic examinations (a summary is given in [Tables 3](#t3-jptm-2016-12-30){ref-type="table"} and [4](#t4-jptm-2016-12-30){ref-type="table"} and the details are given in [Supplementary Table S2](#SD2-jptm-2016-12-30){ref-type="supplementary-material"}), but the proportions were quite different. Internal medicine (13,917,799, 46.29%), general surgery (6,334,913, 21.07%), obstetrics/gynecology (3,444,796, 11.46%), and urology (1,769,651, 5.89%) were the most common medical departments (25,467,159, 84.70%) requesting pathologic examinations. These proportions were similar to those of the previous study \[[@b1-jptm-2016-12-30]\].

A summary and the details of the pathologic examination status according to type of medical institution are listed in [Table 5](#t5-jptm-2016-12-30){ref-type="table"} and [Supplementary Table S3](#SD3-jptm-2016-12-30){ref-type="supplementary-material"}, respectively. The numbers of each type of medical institution were not included in this analysis. The majority of pathologic examinations were frequently performed in a tertiary hospital. Among the different pathologic examinations, biopsy and AC were frequently performed in clinics.

A summary and the details of the pathologic examination status according to the administrative district are listed in [Tables 6](#t6-jptm-2016-12-30){ref-type="table"}, [7](#t7-jptm-2016-12-30){ref-type="table"}, and [Supplementary Table S4](#SD4-jptm-2016-12-30){ref-type="supplementary-material"}, respectively. About 60.3% of pathologic examinations (20,787,770) were requested in medical institutions located in Seoul (12,249,590, 35.5%), Gyeonggi-do (5,517,990, 16.0%), and Busan (3,020,190, 8.8%).

A summary and the details of the pathologic examination status according to the location at which examinations were performed are listed in [Table 8](#t8-jptm-2016-12-30){ref-type="table"} and [Supplementary Table S5](#SD5-jptm-2016-12-30){ref-type="supplementary-material"}, respectively. More than 90% of the resected specimens for malignant tumors requiring gross sectioning (MaligGro) LND, MaligGro LNDX, MAPPING, emergency histopathologic examination during surgery (FS), ENZYME, IHC, CB, and OUTSIDE were performed in their own hospitals. More than half of the biopsies and AC examinations were performed using outside services.

The mean periods between IR requests and the 33, 66, and 99 percentiles IR request inspection completions were 2.2, 2.8, and 6.2 months, respectively. The kernel density estimation plot for each percentile can be found in [Fig. 1](#f1-jptm-2016-12-30){ref-type="fig"}. The 95 and 99 percentile values of the period for 99 percentile IR request inspection completion were 11 and 25 months, respectively.

DISCUSSION
==========

In this study, I investigated various pathologic examination status according to the following categories: annual statistics, requesting department, type of medical institution, administrative district, and location at which pathologic examinations were performed in Korea, 2011--2015. In the last 5 years, the total numbers of MAPPING and IHC increased. These trends reflect the need for a more accurate pathologic diagnosis. Contrary to how the number of conventional cytopathologic examinations decreased, the number of variable liquid-based cytopathologic examinations increased. After FISH and SISH based *HER2* gene examinations were approved by insurance companies in 2013, the number of *HER2* gene examinations increased. These trends reflect both insurance and public health policies.

Throughout many medical institutions in Korea, pathologists will order a large amount of pathologic examinations for diagnosis. However, only 0.04% of pathologic examinations have been claimed by pathologic departments. These discrepancies come from the difference between actual and administrative claims. In tertiary and general hospitals, various medical examinations were requested based on the inpatient department. In clinics, medical examinations were usually requested based on the major disease code of the patient.

According to HIRA (<http://opendata.hira.or.kr/op/opc/olapMdclRcStatsInfo.do>) and the Ministry of the Interior (<http://rcps.egov.go.kr:8081/jsp/stat/ppl_stat_jf.jsp>), there were 53,252 medical institutions and 51,677,054 people in Korea in December, 2015 (see [Supplementary Table S6](#SD6-jptm-2016-12-30){ref-type="supplementary-material"}). The total number of pathologic examinations in each administrative district was positively correlated with both the number of medical institutions and people in the area (both p\<.001). About 61.7% of OUTSIDE were performed in medical institutions located in Seoul. The proportion of OUTSIDE was higher than the population ratio of Seoul (10,022,181, 19.4%). This phenomenon reflects the patient preference for major medical institutions in Seoul.

Compared to previous studies using common pathologic examination codes in 2013 (approximately 5,440,288 pathologic examinations using the NPS data), there was a 3.2% increase in pathologic examinations (5,615,395 pathologic examinations in 2013). This difference was found to be in the acceptable range as determined by the pilot study. When using the raw HIRA data, implementation of basic algorithms using the NPS data is recommended.

In conclusion, even though this survey using the HIRA dataset did not reflect the exact current status, it is still quite accurate. I expect the present study to help with future operations for the Korean Society of Pathology in terms of understanding the current status and trends of pathologic examinations. I recommended that an in-depth analysis of the status of pathologic examinations considering the period between IR requests and inspection completions be made after at least 1 year.
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###### 

Pathologic examination codes using in this study

  Main category   Subcategory                                                                           Claim codes
  --------------- ------------------------------------------------------------------------------------- -------------------------------------------------------
  Biopsy          1--3 pieces/4--6 pieces/7--9 pieces/10--12 pieces/more than 13 pieces                 C5911/C5912/C5913/C5914/C5915
  Non-maligGro    NPB ≤ 6/NPB ≥ 7                                                                       C5916/C5917
  MaligGro LND    NPB ≤ 20/NPB ≥ 21                                                                     C5918/C5919
  MaligGro LNDX   NPB ≤ 15/NPB ≥ 16                                                                     C5500/C5504
  MAPPING         LND/LNDX                                                                              C5505/C5508
  FS              1--2 specimens/3--6 specimens/7--10 specimens/equal and more than 11 specimens        C5511/C5512/C5513/C5514
  BONE            \-                                                                                    C5520
  SPECIAL         Reticulin/Massons' Trichrome/others                                                   C5531/C5532/C5533
  IF              IgG/IgA/IgM/IgE/C3/C4/HBsAg/fibrinogen/others                                         C5541/C5542/C5543/C5544/C5545/C5549/C5546/C5547/C5548
  EM              \-                                                                                    C5550
  ENZYME          ATPase-pH 9.4/ATPase-pH 4.9/NADH/acetylcholinesterase/chloroacetate esterase/others   C5561/C5562/C5563/C5564/C5565/C5566
  Etc.            Et cetera                                                                             \-
  IHC             Interpretation by qualified doctor                                                    C5575006
                  Interpretation by non-qualified doctor                                                C5575
                  HR                                                                                    C5590
                  EGFR pharmDx kit                                                                      CZ503006
                  Morphometric Analysis                                                                 CY552
  CERVIX          Smear/L-based                                                                         C5920/CX541
  BFC             General/using cytospin examination/L-based                                            C5930/C5931/CZ521
  AC              Conventional/L-AC                                                                     C5941/C5943
  CB              After BFC/after AC/L-AC                                                               C5940/C5942/C5944
  HER2 (FISH)     \-                                                                                    C5967
  HER2 (SISH)     \-                                                                                    CZ988
  MSI test        \-                                                                                    CX574
  OUTSIDE         \-                                                                                    Claim code + 009 (subnumber)

Non-maligGro, resected specimen requiring gross sectioning; NPB, number of paraffin blocks; MaligGro, resected specimen for malignant tumor requiring gross sectioning; LND, with lymph node dissection; LNDX, without lymph node dissection; MAPPING, histologic mapping of tumor; FS, emergency histopathologic examination during surgery; BONE, histopathologic examination for bone; SPECIAL, special stain examinations; IF, tissue immunofluorescent microscopic examination; EM, tissue electron microscopy; ENZYME, enzyme histochemistry; IHC, immunohisto(cyto)chemistry; HR, examination of hormone receptor in tissue; CERVIX, cervicovaginal cytopathology; L-, liquid based; BFC, body fluid cytopathology; AC, aspiration cytopathology; CB, cell block; HER2 (FISH), *HER2* gene fluorescence *in situ* hybridization; HER2 (SISH), *HER2* gene silver *in situ* hybridization; MSI, microsatellite instability; OUTSIDE, outside slide interpretation.

###### 

Annual pathologic examination status and trend

  Main category   2011                2012                2013                2014                2015                Total              Growth rates (%) by 2011   Slope        Adjusted R-squared   p-value
  --------------- ------------------- ------------------- ------------------- ------------------- ------------------- ------------------ -------------------------- ------------ -------------------- ---------
  Biopsy          2,084,502 (20.24)   2,092,015 (20.31)   2,086,267 (20.25)   2,052,391 (19.92)   1,985,718 (19.28)   10,300,893 (100)   --4.7                      --23,719.2   .617                 .072
  Non-maligGro    1,269,834 (18.90)   1,371,044 (20.41)   1,349,030 (20.08)   1,340,151 (19.95)   1,388,338 (20.66)   6,718,397 (100)    9.3                        20,611.5     .354                 .172
  MaligGro LND    100,204 (20.04)     106,599 (21.32)     107,083 (21.42)     97,288 (19.46)      88,838 (17.77)      500,012 (100)      --11.3                     --3,204.3    .273                 .212
  MaligGro LNDX   40,003 (18.99)      41,651 (19.77)      42,958 (20.39)      43,528 (20.66)      42,553 (20.20)      210,693 (100)      6.4                        697.7        .524                 .103
  MAPPING         28,429 (15.16)      35,866 (19.12)      38,546 (20.55)      42,042 (22.42)      42,662 (22.75)      187,545 (100)      50.1                       3,464.2      .867                 .014
  FS              111,477 (20.19)     116,373 (21.08)     114,943 (20.82)     107,726 (19.51)     101,583 (18.40)     552,102 (100)      --8.9                      --2,843.5    .424                 .141
  BONE            15,705 (21.11)      15,267 (20.52)      14,275 (19.19)      14,516 (19.51)      14,643 (19.68)      74,406 (100)       --6.8                      --287.5      .462                 .126
  SPECIAL         362,898 (19.53)     364,742 (19.63)     372,751 (20.07)     385,799 (20.77)     371,494 (20.00)     1,857,684 (100)    2.4                        3,824.9      .266                 .216
  IF              59,173 (18.40)      63,043 (19.60)      64,959 (20.20)      66,347 (20.63)      68,110 (21.18)      321,632 (100)      15.1                       2,117.8      .939                 .004
  EM              8,945 (19.07)       9,344 (19.92)       9,452 (20.15)       9,522 (20.30)       9,637 (20.55)       46,900 (100)       7.7                        156.2        .821                 .022
  ENZYME          2,399 (27.80)       1,901 (22.03)       1,437 (16.65)       1,479 (17.14)       1,415 (16.39)       8,631 (100)        --41                       --239        .717                 .044
  IHC             550,773 (17.15)     610,637 (19.01)     653,438 (20.34)     698,083 (21.73)     699,285 (21.77)     3,212,216 (100)    27                         38,447       .909                 .008
  CERVIX          209,750 (17.67)     224,052 (18.88)     226,773 (19.11)     245,152 (20.65)     281,166 (23.69)     1,186,893 (100)    34                         16,393.2     .849                 .017
  BFC             490,524 (18.99)     514,410 (19.92)     511,839 (19.82)     530,399 (20.54)     535,708 (20.74)     2,582,880 (100)    9.2                        10,635.7     .861                 .015
  AC              292,502 (21.91)     314,290 (23.55)     294,545 (22.07)     231,264 (17.33)     202,235 (15.15)     1,334,836 (100)    --30.9                     --26,356     .683                 .053
  CB              117,159 (21.76)     115,878 (21.52)     112,949 (20.98)     103,139 (19.15)     89,320 (16.59)      538,445 (100)      --23.8                     --6,841.7    .817                 .023
  HER2            0 (NA)              0 (NA)              1,176 (10.28)       5,031 (43.96)       5,238 (45.77)       11,445 (100)       NA                         1,550.7      .814                 .023
  MSI             11,837 (20.56)      10,763 (18.70)      10,831 (18.81)      11,919 (20.70)      12,219 (21.22)      57,569 (100)       3.2                        192          --.060               .444
  OUTSIDE         65,609 (18.04)      72,877 (20.04)      75,695 (20.81)      76,649 (21.07)      72,906 (20.04)      363,736 (100)      11.1                       1,836.6      .267                 .215

Values are presented as number (%).

Non-maligGro, resected specimen requiring gross sectioning; MaligGro, resected specimen for malignant tumor requiring gross sectioning; LND, with lymph node dissection; LNDX, without lymph node dissection; MAPPING, histologic mapping of tumor; FS, emergency histopathologic examination during surgery; BONE, histopathologic examination for bone; SPECIAL, special stain examinations; IF, tissue immunofluorescent microscopic examination; EM, tissue electron microscopy; ENZYME, enzyme histochemistry; IHC, immunohisto(cyto)chemistry; CERVIX, cervicovaginal cytopathology; BFC, body fluid cytopathology; AC, aspiration cytopathology; CB, cell block; HER2, *HER2* gene fluorescence *in situ* hybridization and *HER2* gene silver *in situ* hybridization; MSI, microsatellite instability; OUTSIDE, outside slide interpretation.

###### 

Pathologic examination numbers according to requesting department in 2011--2015: part I (sort based on department codes)

  Requesting department                     Biopsy              Non-maligGro        MaligGro LND      MaligGro LNDX    MAPPING           FS                BONE             SPECIAL             IF                EM
  ----------------------------------------- ------------------- ------------------- ----------------- ---------------- ----------------- ----------------- ---------------- ------------------- ----------------- ----------------
  General                                   1,983 (0.02)        1,891 (0.03)        5 (\<0.01)        2 (\<0.01)       0                 0                 3 (\<0.01)       74 (\<0.01)         0                 0
  Internal medicine                         6,743,794 (65.47)   2,094,401 (31.17)   10,822 (2.16)     12,804 (6.08)    101,570 (54.16)   17,044 (3.09)     36,536 (49.10)   1,347,183 (72.52)   219,154 (68.14)   30,851 (65.78)
  Neurology                                 26,860 (0.26)       9,082 (0.14)        78 (0.02)         205 (0.10)       50 (0.03)         573 (0.10)        174 (0.23)       10,438 (0.56)       834 (0.26)        1,083 (2.31)
  Psychiatry                                7,026 (0.07)        1,895 (0.03)        11 (\<0.01)       12 (0.01)        14 (0.01)         32 (0.01)         13 (0.02)        1,245 (0.07)        107 (0.03)        9 (0.02)
  General surgery                           1,309,516 (12.71)   1,679,607 (25.00)   379,207 (75.84)   73,301 (34.79)   57,975 (30.91)    298,270 (54.02)   406 (0.55)       193,095 (10.39)     36,140 (11.24)    5,525 (11.78)
  Orthopedic surgery                        128,100 (1.24)      452,910 (6.74)      649 (0.13)        6,321 (NA)       249 (0.13)        15,707 (2.84)     26,557 (35.69)   19,256 (1.04)       582 (0.18)        287 (0.61)
  Neurosurgery                              56,583 (0.55)       181,773 (2.71)      347 (0.07)        13,422 (6.37)    35 (0.02)         29,625 (5.37)     2,979 (NA)       18,216 (0.98)       673 (0.21)        3,672 (7.83)
  Thoracic surgery                          28,438 (0.28)       100,518 (1.50)      34,694 (6.94)     11,248 (5.34)    2,892 (1.54)      48,875 (8.85)     261 (0.35)       33,537 (1.81)       209 (0.06)        122 (0.26)
  Plastic surgery                           8,598 (0.08)        110,218 (1.64)      1,916 (0.38)      8,022 (3.81)     1,337 (0.71)      14,533 (2.63)     420 (0.56)       4,498 (0.24)        98 (0.03)         56 (0.12)
  Anesthesiology                            1,038 (0.01)        835 (0.01)          10 (\<0.01)       8 (\<0.01)       1 (\<0.01)        20 (\<0.01)       5 (0.01)         110 (0.01)          2 (\<0.01)        0
  Obstetrics and gynecology                 888,109 (8.62)      1,078,597 (16.05)   26,431 (5.29)     16,294 (7.73)    4,194 (2.24)      43,154 (7.82)     53 (0.07)        16,801 (0.90)       136 (0.04)        152 (0.32)
  Pediatrics                                37,839 (0.37)       16,037 (0.24)       118 (0.02)        388 (0.18)       23 (0.01)         1,309 (0.24)      3,856 (5.18)     23,871 (1.28)       16,039 (4.99)     3,784 (8.07)
  Ophthalmology                             20,154 (0.20)       22,715 (0.34)       36 (0.01)         611 (0.29)       10 (0.01)         1,317 (0.24)      14 (0.02)        3,399 (0.18)        132 (0.04)        85 (0.18)
  Otorhinolaryngology                       123,136 (1.20)      396,701 (5.90)      31,590 (6.32)     17,180 (8.15)    464 (0.25)        50,489 (9.14)     148 (0.20)       46,797 (2.52)       254 (0.08)        197 (0.42)
  Dermatology                               340,839 (3.31)      222,969 (3.32)      121 (0.02)        4,481 (2.13)     472 (0.25)        5,487 (0.99)      9 (0.01)         80,731 (4.35)       41,682 (12.96)    70 (0.15)
  Urology                                   286,191 (2.78)      215,571 (3.21)      12,449 (2.49)     45,382 (21.54)   17,938 (9.56)     22,137 (4.01)     70 (0.09)        15,361 (0.83)       1,916 (0.60)      542 (1.16)
  Radiology                                 89,520 (0.87)       7,732 (0.12)        1 (\<0.01)        2 (\<0.01)       1 (\<0.01)        4 (\<0.01)        300 (0.40)       1,113 (0.06)        0                 4 (0.01)
  Radiation oncology                        2,430 (0.02)        113 (\<0.01)        0                 0                0                 1 (\<0.01)        0                202 (0.01)          8 (\<0.01)        1 (\<0.01)
  Pathology                                 391 (\<0.01)        15 (\<0.01)         0                 0                0                 3 (\<0.01)        0                3,249 (0.17)        19 (0.01)         4 (0.01)
  Laboratory medicine                       338 (\<0.01)        46 (\<0.01)         0                 0                0                 0                 24 (0.03)        921 (0.05)          0                 1 (\<0.01)
  Tuberculosis                              233 (\<0.01)        20 (\<0.01)         0                 0                0                 0                 6 (0.01)         122 (0.01)          0                 0
  Rehabilitation medicine                   8,784 (0.09)        4,392 (0.07)        37 (0.01)         181 (0.09)       30 (0.02)         385 (0.07)        104 (0.14)       2,131 (0.11)        500 (0.16)        135 (0.29)
  Nuclear medicine                          118 (\<0.01)        15 (\<0.01)         0                 0                1 (\<0.01)        0                 0                82 (\<0.01)         0                 0
  Family medicine                           146,907 (1.43)      49,855 (0.74)       31 (0.01)         17 (0.01)        240 (0.13)        62 (0.01)         23 (0.03)        26,784 (1.44)       263 (0.08)        10 (0.02)
  Emergency medicine                        15,072 (0.15)       6,035 (0.09)        166 (0.03)        190 (0.09)       41 (0.02)         276 (0.05)        97 (0.13)        5,778 (0.31)        1,381 (0.43)      309 (0.66)
  Occupational and environmental medicine   1,876 (0.02)        98 (\<0.01)         0                 0                0                 0                 1 (\<0.01)       63 (\<0.01)         0                 0
  Preventive medicine                       1,394 (0.01)        4,229 (0.06)        0                 0                2 (\<0.01)        0                 0                3 (\<0.01)          0                 0
  Dental department                         25,596 (0.25)       60,112 (0.89)       1,293 (0.26)      622 (0.30)       6 (\<0.01)        2,799 (0.51)      2,347 (3.15)     2,624 (0.14)        1,503 (0.47)      1 (\<0.01)
  Etc.                                      30 (\<0.01)         15 (\<0.01)         0                 0                0                 0                 0                0                   0                 0
  Summary                                   10,300,893 (100)    6,718,397 (100)     500,012 (100)     210,693 (100)    187,545 (100)     552,102 (100)     74,406 (100)     1,857,684 (100)     321,632 (100)     46,900 (100)

Values are presented as number (%).

Non-maligGro, resected specimen requiring gross sectioning; MaligGro, resected specimen for malignant tumor requiring gross sectioning; LND, with lymph node dissection; LNDX, without lymph node dissection; MAPPING, histologic mapping of tumor; FS, emergency histopathologic examination during surgery; BONE, histopathologic examination for bone; SPECIAL, special stain examinations; IF, tissue immunofluorescent microscopic examination; EM, tissue electron microscopy

###### 

Pathologic examination numbers according to requesting department in 2011--2015: part II (sort based on department codes)

  Requesting department                     ENZYME          IHC                 CERVIX              BFC                 AC                CB                HER2            MSI              OUTSIDE           Summary
  ----------------------------------------- --------------- ------------------- ------------------- ------------------- ----------------- ----------------- --------------- ---------------- ----------------- --------------------
  General                                   0               5 (\<0.01)          363 (0.03)          275 (0.01)          846 (0.06)        13 (\<0.01)       1 (0.01)        0                0                 5,461 (0.02)
  Internal medicine                         2,324 (26.93)   897,900 (27.95)     36,501 (3.08)       1,259,857 (48.78)   622,477 (46.63)   369,897 (68.70)   2,622 (22.91)   3,317 (5.76)     108,745 (29.90)   13,917,799 (46.29)
  Neurology                                 2,312 (26.79)   5,100 (0.16)        1,412 (0.12)        53,245 (2.06)       2,423 (0.18)      1,852 (0.34)      5 (0.04)        8 (0.01)         148 (0.04)        115,882 (0.39)
  Psychiatry                                8 (0.09)        391 (0.01)          666 (0.06)          2,330 (0.09)        435 (0.03)        153 (0.03)        1 (0.01)        2 (\<0.01)       24 (0.01)         14,374 (0.05)
  General surgery                           139 (1.61)      1,413,101 (43.99)   6,204 (0.52)        104,518 (4.05)      489,190 (36.65)   49,603 (9.21)     8,311 (72.62)   53,777 (93.41)   177,028 (48.67)   6,334,913 (21.07)
  Orthopedic surgery                        321 (3.72)      34,131 (1.06)       3,285 (0.28)        35,414 (1.37)       12,788 (0.96)     3,055 (0.57)      13 (0.11)       7 (0.01)         3,004 (0.83)      742,636 (2.47)
  Neurosurgery                              186 (2.16)      95,260 (2.97)       1,915 (0.16)        35,088 (1.36)       3,349 (0.25)      2,957 (0.55)      23 (0.20)       8 (0.01)         825 (0.23)        446,936 (1.49)
  Thoracic surgery                          6 (0.07)        91,268 (2.84)       314 (0.03)          42,808 (1.66)       3,034 (0.23)      13,872 (2.58)     30 (0.26)       92 (0.16)        7,707 (2.12)      419,925 (1.40)
  Plastic surgery                           91 (1.05)       24,684 (0.77)       107 (0.01)          991 (0.04)          482 (0.04)        388 (0.07)        130 (1.14)      2 (\<0.01)       1,254 (0.34)      177,825 (0.59)
  Anesthesiology                            0               58 (\<0.01)         70 (0.01)           371 (0.01)          135 (0.01)        31 (0.01)         0               0                5 (\<0.01)        2,699 (0.01)
  Obstetrics and gynecology                 17 (0.20)       152,242 (4.74)      1,099,372 (92.63)   56,916 (2.20)       28,236 (2.12)     14,401 (2.67)     21 (0.18)       203 (0.35)       19,467 (5.35)     3,444,796 (11.46)
  Pediatrics                                2,489 (28.84)   31,051 (0.97)       116 (0.01)          38,929 (1.51)       1,821 (0.14)      1,494 (0.28)      0               4 (0.01)         1,258 (0.35)      180,426 (0.60)
  Ophthalmology                             63 (0.73)       10,629 (0.33)       59 (\<0.01)         1,608 (0.06)        848 (0.06)        364 (0.07)        1 (0.01)        0                384 (0.11)        62,429 (0.21)
  Otorhinolaryngology                       4 (0.05)        125,340 (3.90)      460 (0.04)          9,871 (0.38)        83,493 (6.25)     27,339 (5.08)     1 (0.01)        7 (0.01)         21,799 (5.99)     935,270 (3.11)
  Dermatology                               197 (2.28)      77,791 (2.42)       308 (0.03)          4,179 (0.16)        3,150 (0.24)      219 (0.04)        7 (0.06)        0                4,957 (1.36)      787,669 (2.62)
  Urology                                   9 (0.10)        193,693 (6.03)      26,181 (2.21)       876,070 (33.92)     31,351 (2.35)     11,392 (2.12)     4 (0.03)        24 (0.04)        13,370 (3.68)     1,769,651 (5.89)
  Radiology                                 2 (0.02)        33,526 (1.04)       298 (0.03)          1,356 (0.05)        31,699 (2.37)     23,850 (4.43)     254 (2.22)      1 (\<0.01)       856 (0.24)        190,519 (0.63)
  Radiation oncology                        0               915 (0.03)          3,773 (0.32)        100 (\<0.01)        155 (0.01)        256 (0.05)        1 (0.01)        9 (0.02)         1,367 (0.38)      9,331 (0.03)
  Pathology                                 1 (0.01)        81 (\<0.01)         1 (\<0.01)          206 (0.01)          3,255 (0.24)      3,488 (0.65)      1 (0.01)        0                10 (\<0.01)       10,724 (0.04)
  Laboratory medicine                       0               7,006 (0.22)        112 (0.01)          22 (\<0.01)         5 (\<0.01)        2 (\<0.01)        0               0                3 (\<0.01)        8,480 (0.03)
  Tuberculosis                              0               75 (\<0.01)         10 (\<0.01)         1,276 (0.05)        43 (\<0.01)       87 (0.02)         0               0                61 (0.02)         1,933 (0.01)
  Rehabilitation medicine                   392 (4.54)      1,884 (0.06)        648 (0.05)          6,636 (0.26)        606 (0.05)        940 (0.17)        10 (0.09)       8 (0.01)         65 (0.02)         27,868 (0.09)
  Nuclear medicine                          0               62 (\<0.01)         7 (\<0.01)          44 (\<0.01)         2,514 (0.19)      682 (0.13)        0               0                58 (0.02)         3,583 (0.01)
  Family medicine                           5 (0.06)        3,524 (0.11)        2,536 (0.21)        16,582 (0.64)       11,341 (0.85)     4,132 (0.77)      1 (0.01)        5 (0.01)         398 (0.11)        262,716 (0.87)
  Emergency medicine                        64 (0.74)       3,939 (0.12)        2,156 (0.18)        31,115 (1.20)       514 (0.04)        7,460 (1.39)      8 (0.07)        95 (0.17)        293 (0.08)        74,989 (0.25)
  Occupational and environmental medicine   0               18 (\<0.01)         1 (\<0.01)          159 (0.01)          81 (0.01)         2 (\<0.01)        0               0                1 (\<0.01)        2,300 (0.01)
  Preventive medicine                       0               5 (\<0.01)          2 (\<0.01)          24 (\<0.01)         188 (0.01)        0                 0               0                1 (\<0.01)        5,848 (0.02)
  Dental department                         1 (0.01)        8,537 (0.27)        15 (\<0.01)         2,875 (0.11)        372 (0.03)        516 (0.10)        0               0                648 (0.18)        109,867 (0.37)
  Etc.                                      0               0                   1 (\<0.01)          15 (\<0.01)         5 (\<0.01)        0                 0               0                0                 66 (\<0.01)
  Summary                                   8,631 (100)     3,212,216 (100)     1,186,893 (100)     2,582,880 (100)     1,334,836 (100)   538,445 (100)     11,445 (100)    57,569 (100)     363,736 (100)     30,066,915 (100)

Values are presented as number (%).

ENZYME, enzyme histochemistry; IHC, immunohisto(cyto)chemistry; CERVIX, cervicovaginal cytopathology; BFC, body fluid cytopathology; AC, aspiration cytopathology; CB, cell block; HER2, *HER2* gene fluorescence *in situ* hybridization and *HER2* gene silver *in situ* hybridization; MSI, microsatellite instability; OUTSIDE, outside slide interpretation.

###### 

Pathologic examination status according to types of medical institutions in 2011--2015

  Pathologic examination   Tertiary hospital    General hospital    Hospital            Convalescent hospital   Clinic              Dental hospital   Dental clinic    Public health center   Public health center and county hospital   Oriental hospital   Summary
  ------------------------ -------------------- ------------------- ------------------- ----------------------- ------------------- ----------------- ---------------- ---------------------- ------------------------------------------ ------------------- ------------------
  Biopsy                   2,354,632 (22.86)    2,617,426 (25.41)   1,387,062 (13.47)   13,460 (0.13)           3,910,624 (37.96)   13,285 (0.13)     898 (0.01)       0                      2,767 (0.03)                               739 (0.01)          10,300,893 (100)
  Non-maligGro             1,727,593 (25.71)    2,362,797 (35.17)   1,161,784 (17.29)   3,929 (0.06)            1,440,209 (21.44)   18,397 (0.27)     384 (0.01)       0                      2,197 (0.03)                               1,107 (0.02)        6,718,397 (100)
  MaligGro LND             332,395 (66.48)      149,342 (29.87)     13,548 (2.71)       2 (\<0.01)              4,032 (0.81)        693 (0.14)        0                0                      0                                          0                   500,012 (100)
  MaligGro LNDX            151,392 (71.85)      56,436 (26.79)      1,999 (0.95)        16 (0.01)               567 (0.27)          282 (0.13)        0                0                      1 (\<0.01)                                 0                   210,693 (100)
  MAPPING                  132,776 (70.80)      52,851 (28.18)      1,705 (0.91)        7 (\<0.01)              205 (0.11)          1 (\<0.01)        0                0                      0                                          0                   187,545 (100)
  FS                       388,171 (70.31)      158,797 (28.76)     3,730 (0.68)        21 (\<0.01)             104 (0.02)          1,279 (0.23)      0                0                      0                                          0                   552,102 (100)
  BONE                     35,926 (48.28)       27,499 (36.96)      9,264 (12.45)       5 (0.01)                333 (0.45)          1,378 (1.85)      1 (\<0.01)       0                      0                                          0                   74,406 (100)
  SPECIAL                  817,633 (44.01)      756,183 (40.71)     57,218 (3.08)       778 (0.04)              224,562 (12.09)     1,301 (0.07)      0                0                      1 (\<0.01)                                 8 (\<0.01)          1,857,684 (100)
  IF                       226,147 (70.31)      91,857 (28.56)      519 (0.16)          503 (0.16)              1,450 (0.45)        1,156 (0.36)      0                0                      0                                          0                   321,632 (100)
  EM                       35,284 (75.23)       11,411 (24.33)      61 (0.13)           0                       144 (0.31)          0                 0                0                      0                                          0                   46,900 (100)
  ENZYME                   7,524 (87.17)        1,093 (12.66)       9 (0.10)            0                       5 (0.06)            0                 0                0                      0                                          0                   8,631 (100)
  IHC                      2,205,781 (68.67)    966,307 (30.08)     25,241 (0.79)       351 (0.01)              9,041 (0.28)        5,481 (0.17)      0                0                      12 (\<0.01)                                2 (\<0.01)          3,212,216 (100)
  CERVIX                   490,880 (41.36)      449,685 (37.89)     70,512 (5.94)       592 (0.05)              174,700 (14.72)     0                 0                3 (\<0.01)             503 (0.04)                                 18 (\<0.01)         1,186,893 (100)
  BFC                      1,201,031 (46.50)    1,053,678 (40.79)   162,061 (6.27)      2,248 (0.09)            161,414 (6.25)      2,319 (0.09)      0                0                      106 (\<0.01)                               23 (\<0.01)         2,582,880 (100)
  AC                       219,121 (16.42)      335,929 (25.17)     152,361 (11.41)     645 (0.05)              626,573 (46.94)     145 (0.01)        1 (\<0.01)       0                      32 (\<0.01)                                29 (\<0.01)         1,334,836 (100)
  CB                       293,874 (54.58)      196,885 (36.57)     20,101 (3.73)       124 (0.02)              27,092 (5.03)       369 (0.07)        0                0                      0                                          0                   538,445 (100)
  HER2                     8,605 (75.19)        2,747 (24.00)       86 (0.75)           6 (0.05)                1 (0.01)            0                 0                0                      0                                          0                   11,445 (100)
  MSI                      49,100 (85.29)       8,318 (14.45)       151 (0.26)          0                       0                   0                 0                0                      0                                          0                   57,569 (100)
  OUTSIDE                  276,885 (76.12)      75,385 (20.73)      1,391 (0.38)        47 (0.01)               9,667 (2.66)        360 (0.10)        0                0                      0                                          1 (\<0.01)          363,736 (100)
  Summary                  10,954,750 (36.43)   9,374,626 (31.18)   3,068,803 (10.21)   22,734 (0.08)           6,590,723 (21.92)   46,446 (0.15)     1,284 (\<0.01)   3 (\<0.01)             5,619 (0.02)                               1,927 (0.01)        30,066,915 (100)

Values are presented as number (%).

Non-maligGro, resected specimen requiring gross sectioning; MaligGro, resected specimen for malignant tumor requiring gross sectioning; LND, with lymph node dissection; LNDX, without lymph node dissection; MAPPING, histologic mapping of tumor; FS, emergency histopathologic examination during surgery; BONE, histopathologic examination for bone; SPECIAL, special stain examinations; IF, tissue immunofluorescent microscopic examination; EM, tissue electron microscopy; ENZYME, enzyme histochemistry; IHC, immunohisto(cyto)chemistry; CERVIX, cervicovaginal cytopathology; BFC, body fluid cytopathology; AC, aspiration cytopathology; CB, cell block; HER2, *HER2* gene fluorescence *in situ* hybridization and *HER2* gene silver *in situ* hybridization; MSI, microsatellite instability; OUTSIDE, outside slide interpretation.

###### 

Pathologic examination status according to administrative districts in 2011--2015: part I (sort based on administrative districts codes)

  Administrative district   Biopsy              Non-maligGro        MaligGro LND      MaligGro LNDX     MAPPING           FS                BONE             SPECIAL           IF                EM
  ------------------------- ------------------- ------------------- ----------------- ----------------- ----------------- ----------------- ---------------- ----------------- ----------------- ----------------
  Etc.                      0                   21 (\<0.01)         0                 0                 0                 0                 0                0                 0                 0
  Seoul                     3,569,090 (30.24)   2,487,048 (32.18)   267,423 (46.34)   113,181 (46.84)   109,012 (50.46)   317,546 (49.92)   22,231 (27.33)   830,214 (37.57)   169,672 (46.92)   26,715 (51.53)
  Busan                     1,007,783 (8.54)    718,747 (9.30)      57,598 (9.98)     26,132 (10.81)    18,263 (8.45)     61,611 (9.69)     9,156 (11.25)    101,122 (4.58)    39,230 (10.85)    5,599 (10.80)
  Incheon                   701,281 (5.94)      457,064 (5.91)      42,029 (7.28)     20,095 (8.32)     12,743 (5.90)     41,553 (6.53)     5,388 (6.62)     158,767 (7.18)    18,329 (5.07)     1,915 (3.69)
  Daegu                     914,814 (7.75)      505,092 (6.54)      43,935 (7.61)     13,662 (5.65)     9,264 (4.29)      35,356 (5.56)     10,090 (12.40)   161,162 (7.29)    22,793 (6.30)     3,466 (6.68)
  Gwangju                   419,909 (3.56)      314,418 (4.07)      9,260 (1.60)      2,575 (1.07)      1,216 (0.56)      7,133 (1.12)      635 (0.78)       31,555 (1.43)     6,476 (1.79)      1,167 (2.25)
  Daejeon                   435,340 (3.69)      309,986 (4.01)      19,421 (3.37)     3,075 (1.27)      3,934 (1.82)      13,359 (2.10)     6,968 (8.56)     66,516 (3.01)     12,276 (3.39)     1,732 (3.34)
  Ulsan                     250,163 (2.12)      168,514 (2.18)      8,207 (1.42)      4,827 (2.00)      138 (0.06)        8,178 (1.29)      2,136 (2.63)     41,843 (1.89)     6,577 (1.82)      698 (1.35)
  Gyeonggi-do               1,978,367 (16.76)   1,287,772 (16.66)   67,488 (11.70)    28,882 (11.95)    37,470 (17.35)    78,222 (12.30)    11,599 (14.26)   436,544 (19.75)   49,950 (13.81)    5,760 (11.11)
  Gangwon-do                228,857 (1.94)      150,249 (1.94)      6,447 (1.12)      3,586 (1.48)      4,503 (2.08)      10,730 (1.69)     3,151 (3.87)     67,670 (3.06)     7,882 (2.18)      758 (1.46)
  Chungcheongbuk-do         250,413 (2.12)      171,847 (2.22)      5,083 (0.88)      1,591 (0.66)      590 (0.27)        5,706 (0.90)      1,927 (2.37)     61,513 (2.78)     2,266 (0.63)      385 (0.74)
  Chungcheongnam-do         313,423 (2.66)      155,444 (2.01)      5,393 (0.93)      2,529 (1.05)      3,700 (1.71)      6,237 (0.98)      177 (0.22)       41,352 (1.87)     6,644 (1.84)      727 (1.40)
  Jeollabuk-do              349,185 (2.96)      192,196 (2.49)      11,396 (1.97)     7,030 (2.91)      4,207 (1.95)      14,340 (2.25)     3,226 (3.97)     20,504 (0.93)     3,829 (1.06)      458 (0.88)
  Jeollanam-do              295,622 (2.50)      177,955 (2.30)      16,774 (2.91)     7,613 (3.15)      30 (0.01)         11,400 (1.79)     245 (0.30)       35,185 (1.59)     1,056 (0.29)      200 (0.39)
  Gyeongsangbuk-do          451,285 (3.82)      220,085 (2.85)      1,936 (0.34)      816 (0.34)        1,159 (0.54)      1,852 (0.29)      1,028 (1.26)     44,136 (2.00)     2,140 (0.59)      270 (0.52)
  Gyeongsangnam-do          532,322 (4.51)      352,022 (4.55)      12,136 (2.10)     5,078 (2.10)      8,698 (4.03)      19,881 (3.13)     2,205 (2.71)     78,121 (3.54)     9,437 (2.61)      1,572 (3.03)
  Jeju                      100,466 (0.85)      57,359 (0.74)       2,538 (0.44)      961 (0.40)        1,094 (0.51)      3,023 (0.48)      1,194 (1.47)     33,540 (1.52)     3,070 (0.85)      426 (0.82)
  Sejong-si                 4,372 (0.04)        3,023 (0.04)        0                 0                 0                 0                 0                104 (\<0.01)      0                 0
  Summary                   11,802,692 (100)    7,728,842 (100)     577,064 (100)     241,633 (100)     216,021 (100)     636,127 (100)     81,356 (100)     2,209,848 (100)   361,627 (100)     51,848 (100)

Values are presented as number (%).

Non-maligGro, resected specimen requiring gross sectioning; MaligGro, resected specimen for malignant tumor requiring gross sectioning; LND, with lymph node dissection; LNDX, without lymph node dissection; MAPPING, histologic mapping of tumor; FS, emergency histopathologic examination during surgery; BONE, histopathologic examination for bone; SPECIAL, special stain examinations; IF, tissue immunofluorescent microscopic examination; EM, tissue electron microscopy.

###### 

Pathologic examination status according to administrative districts in 2011--2015: part II (sort based on administrative districts codes)

  Administrative district   ENZYME          IHC                 CERVIX            BFC                 AC                CB                HER2            MSI              OUTSIDE           Summary
  ------------------------- --------------- ------------------- ----------------- ------------------- ----------------- ----------------- --------------- ---------------- ----------------- --------------------
  Etc.                      0               0                   0                 0                   0                 0                 0               0                0                 21 (\<0.01)
  Seoul                     6,622 (71.09)   1,767,200 (46.85)   543,513 (40.40)   1,146,492 (39.19)   338,246 (22.66)   273,523 (44.02)   6,944 (52.83)   36,679 (55.68)   261,862 (61.69)   12,293,213 (35.55)
  Busan                     521 (5.59)      309,799 (8.21)      106,119 (7.89)    307,125 (10.50)     184,239 (12.34)   42,686 (6.87)     898 (6.83)      6,723 (10.21)    24,460 (5.76)     3,027,811 (8.76)
  Incheon                   144 (1.55)      234,731 (6.22)      86,153 (6.40)     235,529 (8.05)      92,453 (6.19)     38,392 (6.18)     1,297 (9.87)    4,462 (6.77)     19,867 (4.68)     2,172,192 (6.28)
  Daegu                     501 (5.38)      402,725 (10.68)     88,991 (6.62)     131,159 (4.48)      150,027 (10.05)   64,550 (10.39)    815 (6.20)      3,096 (4.70)     22,940 (5.40)     2,584,438 (7.47)
  Gwangju                   136 (1.46)      36,164 (0.96)       38,359 (2.85)     74,981 (2.56)       133,266 (8.93)    4,443 (0.72)      27 (0.21)       0                1,441 (0.34)      1,083,161 (3.13)
  Daejeon                   53 (0.57)       71,899 (1.91)       40,038 (2.98)     83,455 (2.85)       45,632 (3.06)     7,065 (1.14)      194 (1.48)      36 (0.05)        9,240 (2.18)      1,130,219 (3.27)
  Ulsan                     4 (0.04)        46,112 (1.22)       18,427 (1.37)     53,310 (1.82)       30,219 (2.02)     8,665 (1.39)      153 (1.16)      2 (\<0.01)       3,367 (0.79)      651,540 (1.88)
  Gyeonggi-do               849 (9.11)      569,103 (15.09)     219,328 (16.30)   374,113 (12.79)     221,132 (14.81)   92,707 (14.92)    1,820 (13.85)   10,526 (15.98)   58,704 (13.83)    5,530,336 (15.99)
  Gangwon-do                24 (0.26)       63,272 (1.68)       35,913 (2.67)     69,897 (2.39)       15,218 (1.02)     17,189 (2.77)     208 (1.58)      624 (0.95)       1,517 (0.36)      687,695 (1.99)
  Chungcheongbuk-do         0               13,816 (0.37)       11,057 (0.82)     45,783 (1.56)       30,046 (2.01)     8,844 (1.42)      55 (0.42)       371 (0.56)       2,802 (0.66)      614,095 (1.78)
  Chungcheongnam-do         6 (0.06)        26,956 (0.71)       29,260 (2.18)     56,711 (1.94)       23,501 (1.57)     17,295 (2.78)     167 (1.27)      0                2,420 (0.57)      691,942 (2.00)
  Jeollabuk-do              8 (0.09)        71,973 (1.91)       28,958 (2.15)     93,002 (3.18)       54,035 (3.62)     2,377 (0.38)      150 (1.14)      259 (0.39)       3,424 (0.81)      860,557 (2.49)
  Jeollanam-do              3 (0.03)        55,684 (1.48)       27,585 (2.05)     55,997 (1.91)       68,206 (4.57)     5,211 (0.84)      285 (2.17)      798 (1.21)       6,128 (1.44)      765,977 (2.22)
  Gyeongsangbuk-do          10 (0.11)       8,784 (0.23)        26,061 (1.94)     58,344 (1.99)       41,342 (2.77)     6,361 (1.02)      7 (0.05)        1 (\<0.01)       330 (0.08)        865,947 (2.50)
  Gyeongsangnam-do          339 (3.64)      70,854 (1.88)       30,645 (2.28)     109,302 (3.74)      54,687 (3.66)     29,855 (4.80)     92 (0.70)       2,266 (3.44)     5,066 (1.19)      1,324,578 (3.83)
  Jeju                      95 (1.02)       22,901 (0.61)       14,340 (1.07)     30,246 (1.03)       10,421 (0.70)     2,217 (0.36)      33 (0.25)       36 (0.05)        933 (0.22)        284,893 (0.82)
  Sejong-si                 0               5 (\<0.01)          484 (0.04)        129 (\<0.01)        331 (0.02)        12 (\<0.01)       0               0                2 (\<0.01)        8,462 (0.02)
  Summary                   9,315 (100)     3,771,978 (100)     1,345,231 (100)   2,925,575 (100)     1,493,001 (100)   621,392 (100)     13,145 (100)    65,879 (100)     424,503 (100)     34,577,077 (100)

Values are presented as number (%).

ENZYME, enzyme histochemistry; IHC, immunohisto(cyto)chemistry; CERVIX, cervicovaginal cytopathology; BFC, body fluid cytopathology; AC, aspiration cytopathology; CB, cell block; HER2, *HER2* gene fluorescence *in situ* hybridization and *HER2* gene silver *in situ* hybridization; MSI, microsatellite instability; OUTSIDE, outside slide interpretation.

###### 

Summary of the types of institutions where pathologic examinations were done during 2011.2015

  Pathologic examination   Performed in their own hospitals   Performed using outside services   Convalescent hospital   Etc.            Summary
  ------------------------ ---------------------------------- ---------------------------------- ----------------------- --------------- ------------------
  Biopsy                   4,484,330 (43.53)                  5,784,009 (56.15)                  28,542 (0.28)           4,012 (0.04)    10,300,893 (100)
  Non-maligGro             3,621,714 (53.91)                  3,034,515 (45.17)                  61,635 (0.92)           533 (0.01)      6,718,397 (100)
  MaligGro LND             475,825 (95.16)                    20,673 (4.13)                      3,512 (0.70)            2 (\<0.01)      500,012 (100)
  MaligGro LNDX            206,618 (98.07)                    3,252 (1.54)                       821 (0.39)              2 (\<0.01)      210,693 (100)
  MAPPING                  185,267 (98.79)                    1,123 (0.60)                       1,152 (0.61)            3 (\<0.01)      187,545 (100)
  FS                       545,200 (98.75)                    4,089 (0.74)                       2,806 (0.51)            7 (\<0.01)      552,102 (100)
  BONE                     58,330 (78.39)                     13,576 (18.25)                     2,496 (3.35)            4 (0.01)        74,406 (100)
  SPECIAL                  1,487,782 (80.09)                  363,521 (19.57)                    5,793 (0.31)            588 (0.03)      1,857,684 (100)
  IF                       259,628 (80.72)                    58,684 (18.25)                     3,317 (1.03)            3 (\<0.01)      321,632 (100)
  EM                       31,593 (67.36)                     15,175 (32.36)                     132 (0.28)              0               46,900 (100)
  ENZYME                   7,779 (90.13)                      787 (9.12)                         65 (0.75)               0               8,631 (100)
  IHC                      3,129,765 (97.43)                  62,839 (1.96)                      19,503 (0.61)           109 (\<0.01)    3,212,216 (100)
  CERVIX                   901,312 (75.94)                    278,397 (23.46)                    1,057 (0.09)            6,127 (0.52)    1,186,893 (100)
  BFC                      2,068,613 (80.09)                  490,820 (19.00)                    22,888 (0.89)           559 (0.02)      2,582,880 (100)
  AC                       458,090 (34.32)                    855,980 (64.13)                    489 (0.04)              20,277 (1.52)   1,334,836 (100)
  CB                       505,034 (93.79)                    29,688 (5.51)                      3,073 (0.57)            650 (0.12)      538,445 (100)
  HER2                     9,856 (86.12)                      1,587 (13.87)                      2 (0.02)                0               11,445 (100)
  MSI                      35,244 (61.22)                     22,325 (38.78)                     0                       0               57,569 (100)
  OUTSIDE                  356,892 (98.12)                    6,640 (1.83)                       165 (0.05)              39 (0.01)       363,736 (100)
  Summary                  18,828,872 (62.62)                 11,047,680 (36.74)                 157,448 (0.52)          32,915 (0.11)   30,066,915 (100)

Values are presented as number (%).

Non-maligGro, resected specimen requiring gross sectioning; MaligGro, resected specimen for malignant tumor requiring gross sectioning; LND, with lymph node dissection; LNDX, without lymph node dissection; MAPPING, histologic mapping of tumor; FS, emergency histopathologic examination during surgery; BONE, histopathologic examination for bone; SPECIAL, special stain examinations; IF, tissue immunofluorescent microscopic examination; EM, tissue electron microscopy; ENZYME, enzyme histochemistry; IHC, immunohisto(cyto)chemistry; CERVIX, cervicovaginal cytopathology; BFC, body fluid cytopathology; AC, aspiration cytopathology; CB, cell block; HER2, *HER2* gene fluorescence *in situ* hybridization and *HER2* gene silver *in situ* hybridization; MSI, microsatellite instability; OUTSIDE, outside slide interpretation.
